Are you really getting what you pay for when it comes to cannabis products? A shocking new study reveals that nearly half of all cannabis flower products sold in Colorado are mislabeled, often overstating their THC potency. But here's where it gets even more intriguing: while flower products frequently mislead, cannabis concentrates like oils and waxes are surprisingly accurate, with 96% matching their labeled THC content. This raises a critical question: Why the discrepancy?
Published in Scientific Reports, this groundbreaking research is the most comprehensive audit of legal cannabis labeling to date. Conducted in Colorado, the first state to legalize recreational marijuana, the study sheds light on the potency of modern cannabis, the effectiveness of current testing practices, and the gaps that still exist. It’s a wake-up call for both consumers and regulators alike.
But here’s the part most people miss: The study wasn’t just about THC. It also examined other cannabinoids like CBD, CBG, and CBGA, which are often overlooked despite their potential therapeutic benefits. For instance, CBG and CBGA, known for their anti-inflammatory and anti-anxiety properties, were found in higher concentrations than CBD in many products. Yet, only 16% of products included any information about these lesser-known compounds. This begs the question: Are we doing consumers a disservice by fixating solely on THC?
Led by Dr. Cinnamon Bidwell, associate professor of psychology and neuroscience at CU Boulder, the research highlights the complexity of cannabis use and the need for accurate labeling. “While we’re still unraveling the effects of cannabis, the least we can do is provide consumers with truthful information about THC levels,” Bidwell explains. The study, funded by Colorado’s Institute of Cannabis Research and conducted in partnership with MedPharm Research, LLC, involved a ‘secret shopper’ collecting 277 products from 52 dispensaries across 19 counties. These products were then tested by chemists who had no access to the original labels, ensuring unbiased results.
And this is where it gets controversial: Why are flower products so often mislabeled? Some suggest third-party labs might inflate THC numbers to cater to marketers seeking to attract consumers chasing higher potency. However, another explanation lies in the nature of the products themselves. Concentrates are made from homogenous oils, which are easier to test, while flower products are inherently heterogeneous, making accurate testing more challenging. Small tweaks to testing protocols could significantly reduce mislabeling, the researchers argue.
For medical users, inaccurate dosing can be dangerous, while recreational users risk consuming more THC than intended. One product, for example, claimed 24% THC but contained only 16%. While the average discrepancy was just 2%, such inconsistencies can have real-world consequences. In contrast, concentrates were largely accurate, with only 4 out of 99 products mislabeled.
Looking ahead, Bidwell and her team plan to expand their research to include edibles, aiming to improve regulatory standards as more states legalize cannabis. “We all want a trustworthy industry,” says Duncan Mackie, director of pharmacology at MedPharm. “The only way to achieve that is through continuous evaluation and correction.”
Here’s the burning question: Should labels focus solely on THC, or should they include other cannabinoids like CBG and CBGA? Let us know your thoughts in the comments. Are we missing the bigger picture by obsessing over THC alone? The debate is open, and your opinion matters.
